ProCE Banner Activity

Protocol 016: Wk 24 Metabolic and Renal Outcomes Similar for Monthly Oral Islatravir vs Placebo as HIV PrEP in Phase IIa Study

Slideset Download
Conference Coverage
No clinically meaningful differences in metabolic and renal parameters observed between monthly oral placebo and islatravir for PrEP through 24 weeks.

Released: February 16, 2022

Expiration: February 15, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck & Co., Inc.

ViiV Healthcare